CorMedix (CRMD) Therapeutics announced interim results for the Company’s ongoing real-world evidence study being conducted in conjunction with U.S. Renal Care’s, USRC, use of DefenCath in adult hemodialysis patients with central venous catheters. CorMedix and USRC commenced the real-world evidence study upon outpatient commercial launch in July 2024. The study is designed to demonstrate the impact of the broad use of DefenCath in a real-world setting and prospectively assess rates of catheter-related bloodstream infections, as well as hospitalizations secondary to these infections. The study is designed to evaluate these data points for two years. Currently, more than 3,000 patients per month are receiving DefenCath on a routine basis at USRC facilities. CorMedix conducted a preliminary analysis of interim data for approximately 7,000 patients having received at least one dose of DefenCath in Year 1.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRMD:
- Cormedix’s Promising Outlook: Strong Financial Performance, Strategic Acquisition, and Growth Catalysts Justify Buy Rating
- CorMedix price target raised to $18 from $17 at H.C. Wainwright
- CorMedix Inc. Reports Strong Q3 2025 Financial Results
- CorMedix Inc. Reports Record Earnings and Strategic Growth
- Cormedix: Buy Rating Affirmed Amid Strong Sales and Future Growth Catalysts